ZS acquires bioinformatics and systems biology company Intomics A/S

EVANSTON, Illinois, May 04, 2022–(BUSINESSWIRE)–The global professional services company SZ today announced the acquisition of the Danish bioinformatics and systems biology company Intomics. Founded in 2008 in Copenhagen, Denmark, Intomics accelerates and optimizes the discovery and development of pharmaceutical products by enabling the complex analysis of biomedical data. The addition of renowned scientists to the ZS team will reinforce the company’s focus on discovering new medicines for everyone.

International pharmaceutical and biotechnology companies, as well as other biomedical research entities, use Intomics’ service and technology offerings to aid in preclinical work, including target discovery, biomarker identification, repositioning of medications and patient stratification. As the pharmaceutical industry intensifies its efforts in the development of new drugs, the demand for innovative capabilities in disease discovery and biology increases.

Solidly organized and best-in-class, Intomics’ protein-protein interaction network is condition-agnostic and supports personalized biomedical analysis spanning multiple diseases. Scientists and bioinformaticians use the network to understand disease biology at the pathway and molecular level. This leads to new insights and discoveries and accelerates preclinical activities to bring new drugs to patients faster.

“Our strategic acquisition of Intomics will allow us to support our customers in their quest for breakthrough science and innovative medicines that dramatically improve the lives of patients,” said Pratap Khedkar, CEO of ZS. “The unique combination of our extensive data, academic and scientific expertise, technology and artificial intelligence will accelerate drug discovery and increase the likelihood of success for innovative drugs. »

The 42 members of Intomics will join ZS’s staff of 12,000 employees worldwide and strengthen its team of molecular natives who combine scientific, technological and data science expertise with a research mindset to advance the adoption of in silico methods in the field of drug discovery. The addition of Intomics expands ZS’s existing data and technology offerings to increase sophistication and leverage analytics, bioinformatics and applied mathematics to boost the business impact of science. R&D.

“For us, ZS was a natural fit to continue our legacy. Through integration with ZS, we will be able to expand our impact in drug discovery, increase the reach and use of AI in our work with customers, and operate at scale. world while expanding career opportunities for our team members,” said Thomas S. Jensen, Ph.D., CEO and co-founder of Intomics. “Our common roots in academia and our shared values, including our dedication to rigor, a deliberative approach and a desire to do well for both our clients and our staff, made ZS a natural choice for us as for our customers. »

About ZS

ZS is a professional services firm that works alongside companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, cutting-edge analytics, technology and strategy to create solutions that work in the real world. With over 37 years of experience and more than 12,000 people in more than 30 offices around the world, we are passionately committed to helping companies and their customers thrive. To find out more, visit www.zs.com or follow us on Twitter and LinkedIn.

About Intomics

Intomics was founded by world-renowned scientists in the field of bioinformatics and systems biology to accelerate and improve drug discovery and development. We are biologists, bioinformaticians, data scientists and software engineers who share a passion for transforming data into treatments. And that’s what we’ve been proudly doing for over 10 years. We work closely with our clients in the biotech and pharmaceutical industries, and we leverage the synergy between our clients’ disease-specific knowledge and our unique expertise in data analytics and our technology. Together, we are changing the game for patients. It is both our trademark and what motivates Intomics employees.

The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.

View the source version at businesswire.com: https://www.businesswire.com/news/home/20220504005269/en/


Quintin Maidment

We would like to give thanks to the writer of this post for this incredible web content

ZS acquires bioinformatics and systems biology company Intomics A/S

Our social media profiles here and other pages related to them here.https://www.ai-magazine.com/related-pages/